Literature DB >> 32770553

Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7.

Masanori Yoshida1,2, Kanako Tanase-Nakao3, Hirohito Shima3,4, Ryota Shirai1,2, Kaoru Yoshida1, Tomoo Osumi1,5, Takao Deguchi5, Makiko Mori6, Yuki Arakawa6, Masatoshi Takagi7, Takako Miyamura8, Kimiyoshi Sakaguchi9, Hidemi Toyoda10, Hisashi Ishida11, Naoki Sakata12, Toshihiko Imamura13, Yuta Kawahara14, Akira Morimoto14, Takashi Koike15, Hiroshi Yagasaki16, Shuichi Ito2, Daisuke Tomizawa5, Nobutaka Kiyokawa1, Satoshi Narumi3, Motohiro Kato1,5.   

Abstract

Monosomy 7 (-7) occurs in various types of paediatric myeloid disorders and has a poor prognosis. Recent studies have demonstrated that patients with germline gain-of-function SAMD9/9L variants and loss-of-function GATA2 variants are prone to developing myelodysplastic syndrome (MDS) associated with -7. However, the prevalence of the genetic variants among paediatric haematologic disorders with -7 is unknown. The present study screened germline variants of GATA2 and SAMD9/9L in 25 patients with various types of paediatric haematological disorders associated with -7. The diagnoses of the 25 patients included MDS (n = 10), acute myeloid leukaemia (AML) and myeloid sarcomas (n = 9), juvenile myelomonocytic leukaemia (n = 3) and other disorders (n = 3). Seven patients with a germline pathogenic GATA2 variant were found. For SAMD9/9L screening, next-generation sequencing was used to detect low-abundance variants and found four novel germline variants. Functional analysis revealed that three out of the four variants showed growth-restricting capacity in vitro and thus, were judged to be pathogenic. Cases with GATA2 mutation tended to be older, compared to those with SAMD9/9L mutations. In conclusion, GATA2 and SAMD9/9L were sequenced in 25 patients with paediatric haematologic disorders associated with -7, and 40% of them were found to have some pathogenic germline variants in the three genes.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990GATA2zzm321990; zzm321990SAMD9zzm321990; zzm321990SAMD9Lzzm321990; monosomy 7; pediatrics

Mesh:

Substances:

Year:  2020        PMID: 32770553     DOI: 10.1111/bjh.17006

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Somatic mosaicism in inherited bone marrow failure syndromes.

Authors:  Fernanda Gutierrez-Rodrigues; Sushree S Sahoo; Marcin W Wlodarski; Neal S Young
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-27       Impact factor: 3.670

2.  Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.

Authors:  Sushree S Sahoo; Victor B Pastor; Charnise Goodings; Rebecca K Voss; Emilia J Kozyra; Amina Szvetnik; Peter Noellke; Michael Dworzak; Jan Starý; Franco Locatelli; Riccardo Masetti; Markus Schmugge; Barbara De Moerloose; Albert Catala; Krisztián Kállay; Dominik Turkiewicz; Henrik Hasle; Jochen Buechner; Kirsi Jahnukainen; Marek Ussowicz; Sophia Polychronopoulou; Owen P Smith; Oksana Fabri; Shlomit Barzilai; Valerie de Haas; Irith Baumann; Stephan Schwarz-Furlan; Marena R Niewisch; Martin G Sauer; Birgit Burkhardt; Peter Lang; Peter Bader; Rita Beier; Ingo Müller; Michael H Albert; Roland Meisel; Ansgar Schulz; Gunnar Cario; Pritam K Panda; Julius Wehrle; Shinsuke Hirabayashi; Marta Derecka; Robert Durruthy-Durruthy; Gudrun Göhring; Ayami Yoshimi-Noellke; Manching Ku; Dirk Lebrecht; Miriam Erlacher; Christian Flotho; Brigitte Strahm; Charlotte M Niemeyer; Marcin W Wlodarski
Journal:  Nat Med       Date:  2021-10-07       Impact factor: 87.241

3.  Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.

Authors:  Stefania Scicchitano; Ylenia Montalcini; Valeria Lucchino; Valentina Melocchi; Valerio Gigantino; Emanuela Chiarella; Fabrizio Bianchi; Alessandro Weisz; Maria Mesuraca
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.